The FDA gave Antisense a rare pediatric disease designation last month, which makes the treatment eligible for a regulatory voucher that could be traded on secondary markets for hundreds of millions of dollars.Antisense says that ATL1102 could have a “profound” impact on boys with DMD, in slowing the muscle wasting associated with the disease. A phase 2b study is planned for next year..
The FDA gave Antisense a rare pediatric disease designation last...
-
- There are more pages in this discussion • 7 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
10.5¢ |
Change
0.005(5.00%) |
Mkt cap ! $94.66M | |||
| Open | High | Low | Value | Volume |
| 11.0¢ | 11.5¢ | 10.5¢ | $242.1K | 2.246M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 47453 | 10.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 11.0¢ | 278209 | 3 |
View Market Depth
| Last trade - 16.10pm 30/09/2024 (20 minute delay) ? |
| PER (ASX) Chart |